Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Decreases By 38.9%

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant decrease in short interest in July. As of July 15th, there was short interest totaling 54,453 shares, a decrease of 38.9% from the June 30th total of 89,082 shares. Based on an average daily trading volume, of 45,733 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.1% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Estrella Immunopharma presently has an average rating of “Hold” and a consensus target price of $8.00.

Institutional Trading of Estrella Immunopharma

Several institutional investors have recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new position in Estrella Immunopharma in the fourth quarter worth approximately $43,000. State Street Corp increased its stake in Estrella Immunopharma by 93.5% during the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after acquiring an additional 20,900 shares during the last quarter. XTX Topco Ltd raised its position in Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after purchasing an additional 39,099 shares during the period. Marshall Wace LLP purchased a new stake in Estrella Immunopharma in the fourth quarter valued at $88,000. Finally, Geode Capital Management LLC lifted its stake in shares of Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after purchasing an additional 8,318 shares during the last quarter. Hedge funds and other institutional investors own 0.35% of the company’s stock.

Estrella Immunopharma Price Performance

Shares of ESLA traded down $0.01 during mid-day trading on Friday, reaching $0.71. The stock had a trading volume of 6,435 shares, compared to its average volume of 115,332. Estrella Immunopharma has a 52-week low of $0.69 and a 52-week high of $3.15. The firm has a market cap of $30.71 million, a price-to-earnings ratio of -2.10 and a beta of 0.85. The business’s fifty day moving average is $0.97 and its 200 day moving average is $1.15.

Estrella Immunopharma (NASDAQ:ESLA) last issued its earnings results on Saturday, May 16th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. As a group, sell-side analysts anticipate that Estrella Immunopharma will post -0.29 EPS for the current fiscal year.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.